. 2023 Jan 10;10:1097416. doi: 10.3389/fped.2022.1097416

Table 1.

The baseline and perioperative data of 120 patients undergoing SILS.

	Total (n = 120)	Success group^a (n = 103)	Failure group^b (n = 17)	P-value
Gender (%)				0.110
Female	71 (59.17%)	57 (55.34%)	14 (82.35%)
Male	49 (40.83%)	46 (44.66%)	3 (17.65%)
Age (SD), years	8.24 (2.22)	8.03 (2.17)	9.53 (2.12)	0.034^*
Height (SD), cm	129 (15.60)	128 (14.40)	141 (17.40)	0.004^*
Weight (SD), kg	27.9 (9.92)	26.8 (9.06)	34.7 (12.30)	0.010^*
BMI (SD), kg/m²	16.2 (2.55)	16.1 (2.53)	16.9 (2.67)	0.456
Splenic long-axis (SD), cm	20.7 (2.82)	20.7 (2.86)	20.5 (2.67)	0.969
Primary disease (%)				0.896
α-thalassaemia	95 (79.17%)	82 (79.61%)	13 (76.47%)
β-thalassaemia	21 (17.50%)	17 (16.50%)	4 (23.53%)
Hereditary spherocytosis	4 (3.33%)	4 (3.89%)	0 (0%)
Surgical protocol (%)				0.735
SILS-C^c	60 (50.00%)	53 (51.46%)	7.00 (41.18%)
SILS-S^d	60 (50.00%)	50 (48.54%)	10.0 (58.82%)
Operating time (SD), min	189 (48.90)	188 (48.70)	190 (52.05)	0.988
Blood loss (Min, Max), ml	20 (5, 425)	20 (5, 290)	320 (125, 425)	<0.001^*
Pain score at Day 1 (SD)^e	2.93 (0.95)	2.89 (0.91)	3.12 (1.17)	0.663
Pain score at Day 3 (SD)^e	0.975 (0.88)	0.961 (0.89)	1.06 (0.89)	0.915
Anal exhaust time (SD), h	24.7 (8.79)	23.9 (7.73)	29.4 (12.90)	0.061
Postoperative hospital stay (SD), day	4.78 (1.03)	4.72 (1.03)	5.12 (0.99)	0.336
Complications (%)
No	110 (91.67%)	95 (92.23%)	15 (88.24%)	0.858
Yes	10 (8.33%)	8 (7.77%)	2 (11.76%)

^{^a}

Surgery was completed as planned.

^{^b}

Surgery was not completed as planned and intraoperative conversion to other surgical programs.

^{^c}

The SILS with curved surgical instrumentation.

^{^d}

The SILS with straight surgical instrumentation.

^{^e}

FLACC: The primary outcome measure will be the pain rating using the Faces, Legs, Activity, Cry and Consolability Scale during the procedure.

P < 0.05.